Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Clinical trial NCT05292911 · COMPLETED

Trial details

NCT number: NCT05292911
Sponsor: Altimmune, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Alcoholic Fatty Liver Disease

Start date: 2022-03-09
Primary completion: 2022-10-31
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.